Publication | Closed Access
Updated Cost-effectiveness Analysis of PCSK9 Inhibitors Based on the Results of the FOURIER Trial
144
Citations
1
References
2017
Year
Cost-effectiveness AnalysisPharmacotherapyPreventive CardiologyUnited StatesCoronary Artery DiseaseCardiovascular Translational ResearchPublic HealthAtherosclerosisLifetime Analytic HorizonPharmacoeconomicsFourier TrialCost EffectivenessDrug DevelopmentPharmacologyPcsk9 InhibitorsEpidemiologyCardiovascular DiseaseDrug TrialMedicineDrug DiscoveryPharmaceutical Research
This study uses the results of the FOURIER trial to assess the current cost-effectiveness of PCSK9 inhibitors over the lifetime analytic horizon for patients with atherosclerotic cardiovascular disease in the United States.
| Year | Citations | |
|---|---|---|
Page 1
Page 1